Helix has partnered with Databricks to launch Helix Research Workspaces, a Trusted Research Environment for population-scale clinicogenomic research. The platform provides approved partners secure access to analysis tools and compute capabilities for more than 550,000 linked clinicogenomic records. Built on the Databricks Data + AI platform, Research Workspaces gives researchers access to GenoSphere clinicogenomic records, which combine genomic data with an average of over 13 years of electronic health records. The environment features population-scale genomic analysis tools, AI-assisted coding, collaborative workspaces, and integrated oversight capabilities. Helix found that researchers using Research Workspaces had lower compute costs compared to similar work on different platforms. The launch follows Helix's earlier release of Cohort Builder, which enables researchers to build targeted clinical and genomic cohorts.

Your privacy is important to Helix. New research environment gives approved partners secure, governed access to analysis tools and compute capabilities for more than 550,000 linked clinicogenomic records SAN MATEO, Calif., (September 24, 2026) - Helix, the leading enterprise genomics company, today announced a partnership with Databricks, the data and AI company, to launch Helix(R) Research Workspaces, a new Trusted Research Environment (TRE) for population-scale clinicogenomic research. Built natively on the Databricks Data + AI platform, the new Research Workspaces gives approved Helix research partners secure, governed access to compute, storage and analysis tools for more than 550,000 GenoSphere(TM) clinicogenomic records. GenoSphere combines Exome+(R) genomic data with an average of more than 13 years of electronic health records, enriched with medical and pharmacy claims. Population-scale genomic research often requires specialized technical expertise and substantial effort to assemble data and establish an analysis environment. These demands can limit both the pace of discovery and who can participate. The new Research Workspaces TRE brings data and analysis tools into an easy-to-use governed application so researchers can spend less time preparing infrastructure and more time testing hypotheses, interpreting results and building on existing findings. It's designed to support investigating potential targets, discovering biomarkers and characterizing patient populations using GenoSphere datasets. Key capabilities include: * Population-scale genomic analysis with a custom genomic analysis toolkit designed to support large-scale genomic research. * AI-assisted coding: A built-in coding assistant to help researchers develop and refine analysis code more efficiently. * Collaborative research workspaces: Project-based notebooks and workspaces that allow researchers to collaborate with data access controls and monitoring built in. * Integrated oversight: Real-time visibility into analysis progress and compute costs to help researchers to monitor projects within the environment. "What excites me most is the potential to bring data, compute and AI agents together to make science faster, less expensive and accessible to more people," said James Lu, M.D., Ph.D., CEO and co-founder of Helix. "With the Research Workspaces TRE, we want researchers who haven't had access to specialized bioinformatics support to ask new questions, test ideas and replicate findings. Expanding who can participate in discovery is just as important as accelerating the work itself." Helix found that researchers using Research Workspaces TRE had lower compute costs than when they performed similar work on a different platform. Furthermore, AI capabilities can cut down the total time to answer significantly, empowering teams to test additional hypotheses and examine the robustness of their research findings. "Helix is expanding access to population-scale clinicogenomic research to advance precision medicine," said Sarah Branfman, Global VP of ISV at Databricks. "With Databricks' ISV Built On program, Helix is bringing clinical and genomic data together in a governed and scalable environment, helping research partners accelerate insight, personalize care, and improve patient outcomes." The launch builds on Helix's broader investment in research and discovery with a new centralized platform with other built in applications including partner operations and more. Earlier this year, Helix launched Helix(R) Cohort Builder, which enables researchers to build targeted clinical and genomic cohorts through a graphical interface or AI-assisted natural language search. The new Trusted Research Environment builds on those capabilities for deeper population analysis. To learn more about the Helix(R) Research Workspaces, visit helix.com/company/explorer/research-workspaces About Helix: Helix is the leading enterprise genomics platform. The company transforms health systems and enables life science organizations to leverage the power of genomics across their enterprise, creating strategic value and fueling future growth. The Helix Research Network(R)- the largest precision health network in the world - accelerates genomic discoveries and translates them into real-world clinical impact. Learn more at www.helix.com. Helix Media Contact:

Precure selects Helix as multiomics lab and AI tools provider. September 21, 2026 Precure officials say they have selected Helix as its multiomic laboratory and AI tools provider supporting plans to generate molecular data from approximately one million biospecimens. The goal is to accelerate the integration of molecular insights into routine clinical care at the Mayo Clinic and across health systems more broadly. The Mayo Clinic last week launched Precure with founding partner Thermo Fisher Scientific to help transform how the life sciences community understands the biological changes that occur as disease develops before symptoms occur. Precure brings together clinical expertise, de-identified longitudinal health information, and population-scale molecular data to accelerate the development of new approaches with healthcare applications. Helix will provide both advanced AI tools for delivery of genomics into the clinic and biomarker driven research, and population scale multiomic capability that encompasses clinical whole genome sequencing (WGS) and research grade proteome sequencing. Linked with longitudinal clinical information and high performance compute infrastructure, the objective is to create new opportunities for prevention, diagnosis, and treatment, according to Aaron Mangold, MD, chief medical officer, Precure. "Our goal is to generate genomic information that can help inform patient care while creating a powerful resource for discovery," said Mangold. "We are working to make clinical whole genome sequencing and multiomics a foundation of care, helping us detect disease sooner and act earlier." Building on Mayo Clinic's Tapestry study, which utilized Helix's Exome+ sequencing technology and reached 100,000 participants, Precure is extending that collaboration by leveraging Helix's experience providing workflow orchestration, (CLIA/CAP) genomic sequencing, data infrastructure, and AI tools to its health system partners. Precure and Helix have selected Ultima Genomics' UG200(TM) Ultra Sequencing Platform as part of the program's large-scale multiomics initiative. Helix will use a fleet of Ultima's next-generation platforms to generate genomic data for WGS and read-out for proteomics at scale. "The genome is becoming an enduring patient resource, providing a precision baseline for a lifetime of care," noted James Lu, MD, PhD, CEO of Helix. "Helix brings together the laboratory and data capabilities to make this possible at scale." Helix joins Precure as a collaborator and minority owner. Mayo Clinic's involvement in Precure is intended to advance its nonprofit mission. Any financial returns to Mayo Clinic would be reinvested in its mission of patient care, research and education. Visit mayo.edu/research/precure for more information.